As per the report titled ‘Global Heart Failure Disease Market Analysis, 2020’, available with Market Study Report, global heart failure disease market is poised to register substantial growth, with an estimated CAGR of 12.5% over 2020-2025.
 

Rising cases of cardiovascular diseases (CVDs), coupled with increased risks of acquiring these illness owing to lack of balanced diet and exercise, unhealthy lifestyle, surging work stress, weight fluctuations, and escalating smoking and drinking rate are fueling the growth of global heart failure disease market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2767160/
 

As per the treatment types, global heart failure disease market is divided into drug, surgery, and medical devices. Drug segment is further split into calcium channel blockers, aldosterone antagonist, inotropic agents, diuretics, angiotensin receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and others.
 

Medical devices segment is fragmented into heart Pumps, Bi-level positive air pressure device (BiPAP), continuous positive air pressure device (CPAP), Implantable Cardioverter-Defibrillators (ICD), pacemaker, and ventricular assist Device (VAD).
 

Moving to diagnostic test, global heart failure disease market is segmented into blood test, echocardiogram, electrocardiogram (ECG), CT scan & MRI, chest X-ray, and others. Speaking of age group, the market is classified into up to 30 years, 31-64 years, 65 years and above. While on the basis of gender, the market is bifurcated into male, and female.
 

Considering the regional landscape, global heart failure disease market is categorized into North America, Europe, South America, Asia-Pacific, and Middle East & Africa. Among these, North America market is gaining significant traction due to high treatment costs of CVDs in the region. Surging number of heart disorder cases are will further enhance the regional market growth. As per reports published by American Heart Association, the number of people diagnosed with heart failure is estimated to witness a rise of 46%by 2030.
 

Major companies operating in global heart failure disease market are Stealth BioTherapeutics, Bayer AG, AstraZeneca PLC, Bristol Myers Squibb Company, Amgen Inc., Cytokinetics, Inc., Novartis International AG, Merck & Co., Inc., Servier Laboratories, Renova Therapeutics, Inc., and Pfizer Inc.